Enveric Biosciences Inc
Change company Symbol lookup
Select an option...
ENVB Enveric Biosciences Inc
BKE Buckle Inc
ROP Roper Technologies Inc
ESYJY Easyjet PLC
OGE OGE Energy Corp
ASB-E Associated Banc-Corp
LI Li Auto Inc
IKT Inhibikase Therapeutics Inc
GSIT GSI Technology Inc
AZRE Azure Power Global Ltd
Go

Health Care : Pharmaceuticals | Small Cap Value

Enveric Biosciences, Inc. is a biotechnology company. The Company is engaged in the development of novel small-molecule therapeutics for the treatment of anxiety, depression and addiction disorders. The Company through Psybrary has created a robust intellectual property (IP) portfolio of New Chemical Entities (NCEs) for specific mental health indications or physical ailments. The Company's lead program, EB-373, is a next-generation prodrug of psilocin, the active metabolite of psilocybin. EB-373 is a drug candidate from the EVM201 Series advancing through preclinical development for the treatment of anxiety disorders. The Company is also advancing its third generation of therapeutics, the EVM301 Series, that eliminates the psychedelic experience and removes unwanted effects, reducing safety concerns, and hence offering a novel and holistic approach for treating central nervous system disorders.

Price: Delayed
$3.95

Day's Change: 0.00 (0.00%)

Bid: --

Ask: --

B/A Size: --

Day's High: --

Day's Low: --

Volume (Light) Today's volume of 3,438 shares is on pace to be much lighter than ENVB's 10-day average volume of 10,024,817 shares.: 3,438

McCormick & Co. Inc. Stock Falls Wednesday, Underperforms Market

5:10 pm ET March 1, 2023 (MarketWatch) Print

This article was automatically generated by MarketWatch using technology from Automated Insights.

Shares of McCormick & Co. Inc. (MKC) slid 1.82% to $72.97 Wednesday, on what proved to be an all-around mixed trading session for the stock market, with the Dow Jones Industrial Average rising 0.02% to 32,661.84 and the S&P 500 Index falling 0.47% to 3,951.39. This was the stock's second consecutive day of losses. McCormick & Co. Inc. closed $34.38 short of its 52-week high ($107.35), which the company achieved on March 7th.

Trading volume (1.4 M) eclipsed its 50-day average volume of 1.2 M.

Data source: Dow Jones Market Data, FactSet. Data compiled March 1, 2023.

(END) Dow Jones Newswires

March 01, 2023 17:10 ET (22:10 GMT)

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for varies.

Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and